Fluvoxamine is a potent inhibitor of cytochrome P4501A2

Kim Brøsen*, Erik Skjelbo, Birgitte B. Rasmussen, Henrik E. Poulsen, Steffen Loft

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstrakt

Fluvoxamine is a new antidepressant and selectively inhibits serotonin reuptake (SSRI). The present study demonstrates that fluvoxamine is a very potent inhibitor of the high-affinity O-deethylation of phenacetin, which is catalysed by cytochrome P4501A2 (CYP1A2), in microsomes from three human livers. Thus, the apparent inhibitor constant of fluvoxamine, Ki, ranged from 0.12 to 0.24 μM. Seven other SSRIs, citalopram, N-desmethylcitalopram, fluoxetine, norfluoxetine, paroxetine, sertraline and litoxetin either did not inhibit or were weak inhibitors of the O-deethylation of phenacetin. Our findings explain the mechanism of the pharmacokinetic interactions between fluvoxamine and drugs that are metabolized by CYP1A2, e.g. theophylline and imipramine.

OriginalsprogEngelsk
TidsskriftBiochemical Pharmacology
Vol/bind45
Udgave nummer6
Sider (fra-til)1211-1214
Antal sider4
ISSN0006-2952
DOI
StatusUdgivet - 24. mar. 1993

    Fingerprint

Citationsformater

Brøsen, K., Skjelbo, E., Rasmussen, B. B., Poulsen, H. E., & Loft, S. (1993). Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochemical Pharmacology, 45(6), 1211-1214. https://doi.org/10.1016/0006-2952(93)90272-X